EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids

Victoria Ptasinski iD, Susan J Monkley iD, Karolina Öst, Markus Tammia iD, Hani N Alsafadi iD, Catherine Overed-Sayer iD, Petra Hazon, Darcy E Wagner iD, Lynne A Murray iD

Life Science Alliance · 2023-08 · 6 (8) · e202201853

DOI: 10.26508/lsa.202201853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 25.05.2023. Verfasst von Victoria Ptasinski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pluripotent Stem Cells. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Knut och Alice Wallenbergs Stiftelse, Region Skåne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repeated injury of the lung epithelium is proposed to be the main driver of idiopathic pulmonary fibrosis (IPF). However, available therapies do not specifically target the epithelium and human models of fibrotic epithelial damage with suitability for drug discovery are lacking. We developed a model of the aberrant epithelial reprogramming observed in IPF using alveolar organoids derived from human-induced pluripotent stem cells stimulated with a cocktail of pro-fibrotic and inflammatory cytokines. Deconvolution of RNA-seq data of alveolar organoids indicated that the fibrosis cocktail rapidly increased the proportion of transitional cell types including the KRT5 − /KRT17 + aberrant basaloid phenotype recently identified in the lungs of IPF patients. We found that epithelial reprogramming and extracellular matrix (ECM) production persisted after removal of the fibrosis cocktail. We evaluated the effect of the two clinically approved compounds for IPF, nintedanib and pirfenidone, and found that they reduced the expression of ECM and pro-fibrotic mediators but did not completely reverse epithelial reprogramming. Thus, our system recapitulates key aspects of IPF and is a promising system for drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisPluripotent Stem CellsHumansAlveolar Epithelial CellsLungFibrosisOrganoids

Autor:innen und Institutionen

  • Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Department of Experimental Medical Sciences, Lung Bioengineering and Regeneration, Lund University, Lund, Sweden.
  • Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.
  • Lund Stem Cell Center, Lund University, Lund, Sweden.
  • Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Victoria Ptasinski, Susan J Monkley, Markus Tammia, Hani N Alsafadi, Catherine Overed-Sayer, Darcy E Wagner, Lynne A Murray

Förderung

  • Vetenskapsrådet
  • Knut och Alice Wallenbergs Stiftelse
  • Region Skåne

Zitieren

APA

Ptasinski, V., Monkley, S. J., Öst, K., Tammia, M., Alsafadi, H. N., Overed-Sayer, C., Hazon, P., Wagner, D. E., & Murray, L. A. (2023). Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids. Life Science Alliance, 6(8), e202201853. https://doi.org/10.26508/lsa.202201853

Vancouver

Ptasinski V, Monkley SJ, Öst K, Tammia M, Alsafadi HN, Overed-Sayer C, et al. Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids. Life Science Alliance. 2023;6(8):e202201853. doi:10.26508/lsa.202201853

BibTeX
@article{Ptasinski2023,
  author = {Ptasinski, Victoria and Monkley, Susan J and Öst, Karolina and Tammia, Markus and Alsafadi, Hani N and Overed-Sayer, Catherine and Hazon, Petra and Wagner, Darcy E and Murray, Lynne A},
  title = {Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids},
  journal = {Life Science Alliance},
  year = {2023},
  volume = {6},
  number = {8},
  pages = {e202201853},
  doi = {10.26508/lsa.202201853}
}
Kostenlos starten →